Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CVT-510
Tecadenoson · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort B | EXPERIMENTAL | Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort C | EXPERIMENTAL | Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort D | EXPERIMENTAL | Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion |
| Cohort E | EXPERIMENTAL | Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion |
| Name | Type | Description |
|---|---|---|
| Tecadenoson | DRUG | Tecadenoson administered intravenously (i.v.) |
| Esmolol | DRUG | Esmolol low dose infusion according to manufacturer's instructions |
Inclusion Criteria: * Have a diagnosis of atrial fibrillation in need of treatment for rate control * Be able and willing to abstain from any antiarrhythmics, including atrioventricular (AV) nodal blocking agents (except for esmolol per protocol), from no later than 8:00 p.m. on the day prior to do...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
Tecadenoson is being developed for the treatment of atrial fibrillation, a common heart rhythm disorder. It is an investigational small molecule that has been studied in a Phase 2 clinical trial in adults with atrial fibrillation. It is not yet approved for any indication.
Tecadenoson targets ADORA1, the adenosine A1 receptor. It acts as an agonist at this receptor. By activating ADORA1, Tecadenoson is designed to affect cardiac electrical signaling, which is relevant to managing atrial fibrillation.
Tecadenoson is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. Gilead is the sponsor of the clinical program evaluating Tecadenoson in atrial fibrillation.
Tecadenoson is in Phase 2 development. It has completed one Phase 2 clinical trial in atrial fibrillation. There are currently no active trials listed for Tecadenoson. It is an investigational drug and has not been approved by the FDA.
Tecadenoson has been studied in one completed Phase 2 trial, NCT00713401, titled "Safety Study of Tecadenoson to Treat Atrial Fibrillation." The trial enrolled 21 adults in the United States and was a controlled study. No active trials are currently listed.